35
A continuous response BP, HR, FBG, Cholesterol,… GRADED DOSE RESPONSE CURVE

pharma2 وقت الحاجه

Embed Size (px)

Citation preview

Page 1: pharma2 وقت الحاجه

8/4/2019 pharma2 وقت الحاجه

http://slidepdf.com/reader/full/pharma2- 1/38

A continuous response

BP, HR, FBG, Cholesterol,…

GRADED DOSE RESPONSE CURVE

Page 2: pharma2 وقت الحاجه

8/4/2019 pharma2 وقت الحاجه

http://slidepdf.com/reader/full/pharma2- 2/38

% of Maximal

Effect

0

20

40

60

80

100

0 200 400 600 800

Max effect = Emax Effect when all the R are occupied by D

C that gives the half-maximal effect 

E= ----------- 

Emax xC

C+ EC50 

 As C ↑  response

increment ↓ 

0

20

40

60

80

100

1 10 100 1000

% of Maximal

Effect

EC50 

Graded dose-response curves are used to determine:

1.The max efficacy (E max) → highest limit of dose-response relationship on response axis.

2.The potency = The concentration of drug required to produce a specified response

The smaller the EC50 , the greater the potency of the agonist, the lower C needed to

elicit the maximum biological response.

3. Compare the relative potency and efficacy of drugs that produce the same effect.

EC50 

[C]

[C]

Page 3: pharma2 وقت الحاجه

8/4/2019 pharma2 وقت الحاجه

http://slidepdf.com/reader/full/pharma2- 3/38

GRADED DOSE RESPONSE CURVE

    A   >   e    f    f    i   c   a   c   y    t    h   a   n

    B

    B    P   a   r    t    i   a    l    A   g   o   n    i   s

    t

   E   F   F   I   C   A   C   Y

POTENCY 

A > potent B

Page 4: pharma2 وقت الحاجه

8/4/2019 pharma2 وقت الحاجه

http://slidepdf.com/reader/full/pharma2- 4/38

X > potent than Y & Z

    X    &    Z   >   e    f    f    i   c

   a   c   y    t    h   a   n    Y

    X    &    Z   a   r   e   e   q   u   a    l   e    f    f    i   c   a   c   y

 Y> potent than Z

GRADED DOSE RESPONSE CURVE

 Y > potent but

< efficacious than Z

Page 5: pharma2 وقت الحاجه

8/4/2019 pharma2 وقت الحاجه

http://slidepdf.com/reader/full/pharma2- 5/38

QANTAL DOSE RESPONSE CURVE

All-non responses

    %    s   u    b    j   e   c    t   s

   r   e   s   p   o   n

    d    i   n   g

Dose-frequency relationship

Page 6: pharma2 وقت الحاجه

8/4/2019 pharma2 وقت الحاجه

http://slidepdf.com/reader/full/pharma2- 6/38

QANTAL DOSE RESPONSE CURVE: used to determine

at which 50% of individuals exhibit the specified therapeutic response

Therapeutic Index The relation between dose to induce a desired

effect versus that producing the unwanted effect. 

TD50

ED50

When low → the drug has a narrow margin of safety digoxin 

When high → the drug has a safe profile diazepam 

0

20

40

60

80

100

1 10 100 1000

[Dose]

ED50 

    %

    s   u    b    j   e   c    t   s   r   e   s   p   o   n    d    i   n   g

TD50 LD50 Median toxic dose

Median lethal dose

Median EffectiveDose

Therapeutic EffectToxic Effect

Lethal Effect

Page 7: pharma2 وقت الحاجه

8/4/2019 pharma2 وقت الحاجه

http://slidepdf.com/reader/full/pharma2- 7/38

Types

Physiological

Chemical

Pharmacokinetic

Non-Competitive

It is the diminution or the complete abolishment of the effect of one drug in the presence of another.

Receptor Blockade (Competitive )

Two drugs react chemically resulting in loss of activity of activedrug

Dimercaprol reduces heavy metal toxicity [ lead, cadmium ….]

Two drugs possess opposing actions in the body, so tend to

cancel each other’s effect

The antagonist effectively reduces the concentrationof the active drug at the site of action

Phenobarbitone induces an accelerated hepatic metabolism warfarine

Nor adrenaline & histamine Omeprozole & histamine

 ANTAGONISM

Page 8: pharma2 وقت الحاجه

8/4/2019 pharma2 وقت الحاجه

http://slidepdf.com/reader/full/pharma2- 8/38

Receptor

Blockade

Competitive

Non-

Competitive

Antagonist prevents binding of agonist to the

receptor at the same binding site ( = competes withit at same occupancy site )

Antagonist block at some point

the chain of events that ignite

the response of  agonist 

Agonist and Antagonist can be bound simultaneously

Agonist and Antagonist compete ( only one is bound)

 ANTAGONISM

Irreversible

Reversible

Page 9: pharma2 وقت الحاجه

8/4/2019 pharma2 وقت الحاجه

http://slidepdf.com/reader/full/pharma2- 9/38

Reversible

Antagonist readily dissociate from binding site of 

agonist to the receptor 

Antagonist form stable, permanent / near permanent chemical

bond with receptor.

Inactivation lasts for duration of receptor turnover or its de-novo synthesis → explains its longevity of action 

Antagonism can be overcomed by increasing

concentration of agonist = Surmountable

Naloxone vs morphine

Phenoxybenzamine & Noradrenaline

Atropine vs Ach

Irreversible

COMPETATIVE ANTAGONISM

Page 10: pharma2 وقت الحاجه

8/4/2019 pharma2 وقت الحاجه

http://slidepdf.com/reader/full/pharma2- 10/38

Parallel shift to the right, without any change in slope or maximum

No parallel shift

But both a decrease in slope and a reduced maximum are obtained.

Competitive Antagonism

Irreversible

Reversible

Page 11: pharma2 وقت الحاجه

8/4/2019 pharma2 وقت الحاجه

http://slidepdf.com/reader/full/pharma2- 11/38

Agonist

Agonist +  irreversible competitiveantagonist

Agonist + non-competitiveantagonist

0

20

40

60

80

100

1 10 100 1000

% of Maximal

Effect

[C]

 Antagonism cannot be overcomed by increasing concentration of agonist = NON-

SURMOUNTABLE

Agonist +  reversible competitiveantagonist

Competitive vs Noncompetative Antagonism

Depression of maximal

response +/- rightward

shifts ( if some R are spare )

 Antagonism can be overcomed by increasing concentration of agonist = SURMOUNTABLE

Verapamil  vs noradrenaline

Page 12: pharma2 وقت الحاجه

8/4/2019 pharma2 وقت الحاجه

http://slidepdf.com/reader/full/pharma2- 12/38

Page 13: pharma2 وقت الحاجه

8/4/2019 pharma2 وقت الحاجه

http://slidepdf.com/reader/full/pharma2- 13/38

By the end of this lecture you will be able to :

Classify receptors into their main superfamilies

Identify the nature & time frame of their response

Recognize their different transduction mechanism

ilos

Page 14: pharma2 وقت الحاجه

8/4/2019 pharma2 وقت الحاجه

http://slidepdf.com/reader/full/pharma2- 14/38

1.Recognition

2.Reception

3.Transduction

4.Response

A RECEPTOR

 Coupler 

Transduction

Direct

 

Its Structure:

1

2 3 4

Page 15: pharma2 وقت الحاجه

8/4/2019 pharma2 وقت الحاجه

http://slidepdf.com/reader/full/pharma2- 15/38

Location

Structure

Transduction Mechanism

Classified according to their 

Time scale of Response 4 Main SUPERFAMILIES 

Channel-Linked Receptor

G-Protein Coupled Receptors

Nuclear Receptors

Enzyme-Linked Receptors

Nature of Response

Page 16: pharma2 وقت الحاجه

8/4/2019 pharma2 وقت الحاجه

http://slidepdf.com/reader/full/pharma2- 16/38

Conductance Cell Signal  Transcription& Translation

Cell Signal   

Hours /Days

Minutes / Hours

1 2 3 4

Channel-Linked G-Protein Coupled Enzyme-Linked Nuclear

Page 17: pharma2 وقت الحاجه

8/4/2019 pharma2 وقت الحاجه

http://slidepdf.com/reader/full/pharma2- 17/38

Channel-Linked Receptor1

Ionotropic Receptor

Ligand-Gated-Ion Channel

Different from Voltage-Gated Ion Channel

Is activated by a change in action potential not by occupancy of a ligand 

Involved in fast synaptic neurotransmission occurring

over millisecondsIt is activated directly when a ligand binds to the

receptor to open the channel that is incorporated as

part of its structure. Examples;

Nicotinic Ach receptor activated by AchGABA A receptor activated by benzodiazipines

NMDA receptor inhibited by glycine

Page 18: pharma2 وقت الحاجه

8/4/2019 pharma2 وقت الحاجه

http://slidepdf.com/reader/full/pharma2- 18/38

G-

Protein

G-Protein-Coupled Receptor

Metabotropic Receptor

PHOSPHORYLATION OF TARGET PROTEINS

Involved in less rapid transmission of mAch R, amine transmitters, Adr R, Dopa-minergic R, histamine R, 5-HT R…Neuropeptide R, prostanoid R, purine R,… Hormones; glycogen

Adenyl cyclase (AC) cAMP PKAPhospholipase C (PLC)IP3 Ca++ intacellular 

Ca2+ /CaMCAMPKDAG PKC

An enzyme 2nd messenger    

RESPONSE

Go-between proteins

Coupler

Agonist

2Composed of 3 subunits

[  g] + GDP

 

Page 19: pharma2 وقت الحاجه

8/4/2019 pharma2 وقت الحاجه

http://slidepdf.com/reader/full/pharma2- 19/38

g

ATP ATPATPATP

G-Protein

R

E

PKA

G-Protein-Coupled Receptor

Adenyle cyclase

g ATP ATPATPATP

R

E

cAMP

P

Channels

P

P Phosphorylate

Proteins

P

Not activated

Ligand binding activates it

Page 20: pharma2 وقت الحاجه

8/4/2019 pharma2 وقت الحاجه

http://slidepdf.com/reader/full/pharma2- 20/38

g

E

Phospholypase C

PIP2 DAG

 

Phosphatidic aInositol

↑ 

G-Protein-Coupled Receptor

IP3

Ca++

PKC 

+CaM 

Enzymes

Cytoskeletal Proteins

P

Channels

P

P

P

Page 21: pharma2 وقت الحاجه

8/4/2019 pharma2 وقت الحاجه

http://slidepdf.com/reader/full/pharma2- 21/38

RESPONSE

Page 22: pharma2 وقت الحاجه

8/4/2019 pharma2 وقت الحاجه

http://slidepdf.com/reader/full/pharma2- 22/38

mAch; m1, m2, m3, m4,

Adrenergic receptors; 1 & 2 / 1 & 25-HT1; 5-HT1A  – 1D receptor 

G-Protein-Coupled Receptor

Different Classes of Receptors

Different Receptors Subtypes

Ach R  m Adrenergic R   &  Dopaminergic R  D1 & D2 5-HT  5-HT1-2 / 5-HT 4-7 

Different in G-Protein Classes

Are the Most Abundant Type

Divided according to their α

-subunits  into Gs, Gi and Gq Gs and Gi produce, respective, stimulation and inhibition of AC

Gq is linked to activation of PLC-IP3 -Ca++ CaM & PKC

Show selectivity to receptors & effectors with which they couple

The a  1 Adrenoceptors couple to Gq to stimulate PLC.

Page 23: pharma2 وقت الحاجه

8/4/2019 pharma2 وقت الحاجه

http://slidepdf.com/reader/full/pharma2- 23/38

++

PLC GqGq

Bronchi Blood Vessel

PLC

G-Protein-Coupled Receptor

+

AC

Adrenoceptor 2 Adrenoceptor 

Inhibitory Receptor Stimulatory Receptor 

Adr 

GsGi

↑cAMP cAMP 

1 Adrenoceptor M1 Ach receptor 

Stimulatory Receptor Stimulatory Receptor 

↑Ca ++

Adr Ach

↑Ca ++

Page 24: pharma2 وقت الحاجه

8/4/2019 pharma2 وقت الحاجه

http://slidepdf.com/reader/full/pharma2- 24/38

1, 2 & AdrenoceptorsDiffer from each other both in ligand selectivity amongdrugs and in coupling to G proteins (Gq, Gi, and Gs,

respectively)M1 and M3 Ach receptors activate the Gq-PLC-IP3-Ca2+ pathwayM2 and M4 Ach receptors activate Gi to reduce the

activity of AC

Page 25: pharma2 وقت الحاجه

8/4/2019 pharma2 وقت الحاجه

http://slidepdf.com/reader/full/pharma2- 25/38

Enzyme-Linked Receptors3

Involved in slow action of; hormones (insulin), growth factors, cytokines, ….. 

Their cytosolic domain either:

Associate directly with an enzyme (guanyl cyclase)

Possess intrisic kinase activity (as tyrosine or serine/threonine kinase) thatcan phosphorylate itself & / or other proteins that they dock.

They control many cellular 

functions as motility, growth,differentiation, division &morphogenesis.

This usually require manyintracellular signaling steps

that take time to process.

Tyrosine Kinase-Linked Receptors

Page 26: pharma2 وقت الحاجه

8/4/2019 pharma2 وقت الحاجه

http://slidepdf.com/reader/full/pharma2- 26/38

Phosphorylate other 

proteins that it docks

Activated Receptor 

autophosphorylates

Ligands cross link or 

dimerize receptors

Tyrosine Kinase-Linked Receptors

Enzyme-Linked Receptors3

Phosphory

lateddockedproteins

Phosphorylates

other targets

RESPONSE

Examples

Insulin receptors

Growth factors

receptors

Page 27: pharma2 وقت الحاجه

8/4/2019 pharma2 وقت الحاجه

http://slidepdf.com/reader/full/pharma2- 27/38

Enzyme-Linked Receptors3

Guanyle cyclase-Linked Receptors

Atrial Natriueretic Peptide [ANP] RECEPTORS

They that have a single transmembrane spanning element.

These have integral intrinic guanylate cyclase activity .

Their 2nd messenger is cGMP 

→ activates PKG → phosphorylate down stream

protein signaling molecules.

↑cGMP 

Page 28: pharma2 وقت الحاجه

8/4/2019 pharma2 وقت الحاجه

http://slidepdf.com/reader/full/pharma2- 28/38

Nuclear Receptors4Are intra-cellularly located whether in cytosol or the nucleus.

Their ligands are usually either:

Extracellular lipophylic hormones; steroids, thyroids, …etc Intracellular 2nd messenger developed along signalingcascade of cell membrane receptors.

They possess a conserved areathat recognizes specific DNA

sequence in the nucleus→ once bound to their ligandsthey react as

TRANSCRIPTION FACTORSexpressing or repressing

target genes.

By this they are involved in

regulation of PROTEIN SYNTHESIS

→so are the most slowest in action. 

Protein

Transcription

Translation

Page 29: pharma2 وقت الحاجه

8/4/2019 pharma2 وقت الحاجه

http://slidepdf.com/reader/full/pharma2- 29/38

Nuclear Receptors4

The activated GR complex

 Up-regulates expression of anti-inflammatory proteins

 Represses expression of pro-inflammatory

proteins in cytosol ( preventing the translocation

of other transcription factors from the cytosol

into the nucleus).

GLUCOCORTICOIDRECEPTOR

proteins

In Cytosol

Page 30: pharma2 وقت الحاجه

8/4/2019 pharma2 وقت الحاجه

http://slidepdf.com/reader/full/pharma2- 30/38

THYROID HORMONE

RECEPTOR

Nuclear Receptors4

Intra nuclear

Page 31: pharma2 وقت الحاجه

8/4/2019 pharma2 وقت الحاجه

http://slidepdf.com/reader/full/pharma2- 31/38

Quiz? 

• An example of an agent thatexerts much of its effectsthrough intracellular receptors

that in complex form binds toDNA response elements:

• A) acetylcholineB) dopamineC) corticosteroidsD) diltiazemE) atropine

Page 32: pharma2 وقت الحاجه

8/4/2019 pharma2 وقت الحاجه

http://slidepdf.com/reader/full/pharma2- 32/38

Quiz? 

• Example(s) of endogenousligands that interact withmembrane-integrated ionchannels and affect(s) ionconductance.

• A) acetylcholineB) GABAC) glutamateD) aspartate

E) glycine

Page 33: pharma2 وقت الحاجه

8/4/2019 pharma2 وقت الحاجه

http://slidepdf.com/reader/full/pharma2- 33/38

Quiz? 

• Example(s) of anintracellular receptor:

 –

? beta-adrenergic receptor – ? muscarinic cholinergic

receptor

 – ? steroid receptor

Page 34: pharma2 وقت الحاجه

8/4/2019 pharma2 وقت الحاجه

http://slidepdf.com/reader/full/pharma2- 34/38

Quiz? 

• Example(s) of agents thataffect ion conductance --affecting cellular membranepotentials

 – ? acetylcholine

 – ? gamma-aminobutyric

acid (GABA)

 – ? aspartate

 – ? glutamate 

Page 35: pharma2 وقت الحاجه

8/4/2019 pharma2 وقت الحاجه

http://slidepdf.com/reader/full/pharma2- 35/38

Quiz? 

• Regulatory moleculesinfluenced by G proteinsystems:

 – ? adenylyl cyclase

 – ? phospholipase A2,C,D

 – ? calcium, potassium,

sodium ion channels

 – ? transport proteins 

Page 36: pharma2 وقت الحاجه

8/4/2019 pharma2 وقت الحاجه

http://slidepdf.com/reader/full/pharma2- 36/38

Quiz? 

• Longer-lastingphysiological responseto drug:

• A) increase in heart ratefollowing epinephrineinfusionB) changes in geneproduct productionfollowing corticosteroid

injection.

Page 37: pharma2 وقت الحاجه

8/4/2019 pharma2 وقت الحاجه

http://slidepdf.com/reader/full/pharma2- 37/38

Quiz? 

• Signal transductioninvolves G proteincoupled receptorsystems:

• A) biogenic aminesB) peptide hormonesC) steroid hormones

• D) insulin

Page 38: pharma2 وقت الحاجه

8/4/2019 pharma2 وقت الحاجه

http://slidepdf.com/reader/full/pharma2- 38/38

Quiz? 

• Growth factors and insulinexert their signalling effectvia:-

A. Calcium channels

B. G-protein

C. Tyrosine kinase

D. DNA transcription